Matches in SemOpenAlex for { <https://semopenalex.org/work/W3122018306> ?p ?o ?g. }
- W3122018306 endingPage "e229" @default.
- W3122018306 startingPage "e222" @default.
- W3122018306 abstract "Background: The advanced-generation, broad-spectrum, intravenous (IV) cephalosporin, ceftobiprole, is an effective and well-tolerated treatment for adults with hospital-acquired pneumonia (HAP) or community-acquired pneumonia (CAP), but its effects in pediatric patients have not been established. Methods: In this multicenter, investigator-blinded, active-controlled, phase 3 study, patients 3 months to <18 years old with HAP or CAP requiring hospitalization were randomized (2:1) to ceftobiprole versus standard-of-care (SoC) IV cephalosporin treatments (ceftazidime or ceftriaxone), with or without vancomycin. After at least 3 days’ IV treatment, patients demonstrating clinical improvement could be switched to an oral antibiotic, to complete a minimum of 7 days’ treatment. Results: Overall, 138 patients were randomized to ceftobiprole (n = 94) or a SoC cephalosporin (n = 44). Median time to oral switch was 6.0 days in the ceftobiprole group and 8.0 days in the SoC cephalosporin group. While on IV therapy, adverse events and treatment-related adverse events were reported by 20.2% and 8.5% of ceftobiprole-treated patients and 18.2% and 0% of SoC cephalosporin-treated patients. Early clinical response rates at day 4 in the intention-to-treat population were 95.7% and 93.2% (between-group difference, 2.6%; 95% confidence interval, –5.5% to 14.7%) in the ceftobiprole and comparator groups, and clinical cure rates at the test-of-cure visit were 90.4% and 97.7% (between-group difference, –7.3%; 95% confidence interval, –15.7% to 3.6%), respectively. Conclusions: Ceftobiprole was well tolerated and, in this small phase 3 study, demonstrated similar efficacy to SoC cephalosporins in pediatric patients with HAP or CAP requiring hospitalization." @default.
- W3122018306 created "2021-02-01" @default.
- W3122018306 creator A5024008506 @default.
- W3122018306 creator A5031978528 @default.
- W3122018306 creator A5042914510 @default.
- W3122018306 creator A5047558403 @default.
- W3122018306 creator A5050156373 @default.
- W3122018306 creator A5054873598 @default.
- W3122018306 creator A5076511543 @default.
- W3122018306 date "2021-01-21" @default.
- W3122018306 modified "2023-09-24" @default.
- W3122018306 title "A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients" @default.
- W3122018306 cites W1495642555 @default.
- W3122018306 cites W1595793822 @default.
- W3122018306 cites W1976231974 @default.
- W3122018306 cites W1977342232 @default.
- W3122018306 cites W1990448757 @default.
- W3122018306 cites W2004207935 @default.
- W3122018306 cites W2015539970 @default.
- W3122018306 cites W2022256930 @default.
- W3122018306 cites W2024175754 @default.
- W3122018306 cites W2039193912 @default.
- W3122018306 cites W2042142189 @default.
- W3122018306 cites W2095034572 @default.
- W3122018306 cites W2114034330 @default.
- W3122018306 cites W2115597546 @default.
- W3122018306 cites W2116068468 @default.
- W3122018306 cites W2147634646 @default.
- W3122018306 cites W2150069228 @default.
- W3122018306 cites W2162578723 @default.
- W3122018306 cites W2164552925 @default.
- W3122018306 cites W2302118651 @default.
- W3122018306 cites W2319021558 @default.
- W3122018306 cites W2336143177 @default.
- W3122018306 cites W2341045795 @default.
- W3122018306 cites W2410718400 @default.
- W3122018306 cites W2803709395 @default.
- W3122018306 cites W2809388401 @default.
- W3122018306 cites W2894320882 @default.
- W3122018306 cites W2901989937 @default.
- W3122018306 cites W2912211359 @default.
- W3122018306 doi "https://doi.org/10.1097/inf.0000000000003077" @default.
- W3122018306 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8104010" @default.
- W3122018306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33480665" @default.
- W3122018306 hasPublicationYear "2021" @default.
- W3122018306 type Work @default.
- W3122018306 sameAs 3122018306 @default.
- W3122018306 citedByCount "5" @default.
- W3122018306 countsByYear W31220183062021 @default.
- W3122018306 countsByYear W31220183062023 @default.
- W3122018306 crossrefType "journal-article" @default.
- W3122018306 hasAuthorship W3122018306A5024008506 @default.
- W3122018306 hasAuthorship W3122018306A5031978528 @default.
- W3122018306 hasAuthorship W3122018306A5042914510 @default.
- W3122018306 hasAuthorship W3122018306A5047558403 @default.
- W3122018306 hasAuthorship W3122018306A5050156373 @default.
- W3122018306 hasAuthorship W3122018306A5054873598 @default.
- W3122018306 hasAuthorship W3122018306A5076511543 @default.
- W3122018306 hasBestOaLocation W31220183061 @default.
- W3122018306 hasConcept C126322002 @default.
- W3122018306 hasConcept C141071460 @default.
- W3122018306 hasConcept C168563851 @default.
- W3122018306 hasConcept C197934379 @default.
- W3122018306 hasConcept C2776520383 @default.
- W3122018306 hasConcept C2777914695 @default.
- W3122018306 hasConcept C2778980435 @default.
- W3122018306 hasConcept C2779489039 @default.
- W3122018306 hasConcept C44249647 @default.
- W3122018306 hasConcept C501593827 @default.
- W3122018306 hasConcept C523546767 @default.
- W3122018306 hasConcept C54355233 @default.
- W3122018306 hasConcept C64778159 @default.
- W3122018306 hasConcept C71924100 @default.
- W3122018306 hasConcept C86803240 @default.
- W3122018306 hasConcept C89423630 @default.
- W3122018306 hasConceptScore W3122018306C126322002 @default.
- W3122018306 hasConceptScore W3122018306C141071460 @default.
- W3122018306 hasConceptScore W3122018306C168563851 @default.
- W3122018306 hasConceptScore W3122018306C197934379 @default.
- W3122018306 hasConceptScore W3122018306C2776520383 @default.
- W3122018306 hasConceptScore W3122018306C2777914695 @default.
- W3122018306 hasConceptScore W3122018306C2778980435 @default.
- W3122018306 hasConceptScore W3122018306C2779489039 @default.
- W3122018306 hasConceptScore W3122018306C44249647 @default.
- W3122018306 hasConceptScore W3122018306C501593827 @default.
- W3122018306 hasConceptScore W3122018306C523546767 @default.
- W3122018306 hasConceptScore W3122018306C54355233 @default.
- W3122018306 hasConceptScore W3122018306C64778159 @default.
- W3122018306 hasConceptScore W3122018306C71924100 @default.
- W3122018306 hasConceptScore W3122018306C86803240 @default.
- W3122018306 hasConceptScore W3122018306C89423630 @default.
- W3122018306 hasIssue "6" @default.
- W3122018306 hasLocation W31220183061 @default.
- W3122018306 hasLocation W31220183062 @default.
- W3122018306 hasLocation W31220183063 @default.
- W3122018306 hasLocation W31220183064 @default.
- W3122018306 hasOpenAccess W3122018306 @default.
- W3122018306 hasPrimaryLocation W31220183061 @default.